| Literature DB >> 33425617 |
Hani I Naga1,2, Joseph A Mellia2,3, Fortunay Diatta1,2, Sammy Othman2,4, Viren Patel2, Jeffrey E Janis5, B Todd Heniford6, John P Fischer2.
Abstract
The prevalence of complex abdominal wall defects continues to rise, which necessitates increasingly sophisticated medical and surgical management. Insurance coverage for reconstructive surgery varies due to differing interpretations of medical necessity. The authors sought to characterize the current insurance landscape for a subset of key adjunctive procedures in abdominal wall reconstruction, including component separation and simultaneous ventral hernia repair with panniculectomy (SVHR-P) or abdominoplasty (SVHR-A), and synthesize a set of reporting recommendations based on insurer criteria.Entities:
Year: 2020 PMID: 33425617 PMCID: PMC7787284 DOI: 10.1097/GOX.0000000000003309
Source DB: PubMed Journal: Plast Reconstr Surg Glob Open ISSN: 2169-7574
Approval and Denial Trends by Indication
| Indication | Coverage Status | No. Companies (%) | |
|---|---|---|---|
| Prevention of hernia formation/recurrence | Approved indication | 1 (2%) | |
| Denied | Experimental/investigational | 9 (18%) | |
| No explanation | 2 (4%) | ||
| No specific policy | 38 (78%) | ||
| Enhance exposure in surgery | Approved indication | 3 (6%) | |
| Denied | Experimental/investigational | 9 (18%) | |
| No explanation | 7 (14%) | ||
| No specific policy | 31 (62%) | ||
| Optimize post-operative wound healing | Approved indication | 3 (6%) | |
| Denied | Experimental/investigational | 3 (6%) | |
| No explanation | 0 (0%) | ||
| No specific policy | 44 (88%) | ||
Summary of Reporting Recommendations for VHR When in Conjunction with Panniculectomy to Help Differentiate from Purely Cosmetic Abdominoplasty
| Insurance Provider | Hernia Characteristics | |||||
|---|---|---|---|---|---|---|
| Size | Reducible | Pain/Other Symptoms | Diastasis | Fascial Defect | Fascial Defect Size | |
| Aetna | Y | Y | Y | Y | Y | Y |
| BCBS KC | Y | Y | Y | Y | Y | Y |
| BCBS KS | Y | Y | Y | N | Y | N |
| BCBS Regence | N | Y | Y | N | Y | N |
| GEHA | Y | Y | Y | Y | Y | Y |
| Highmark | Y | Y | Y | N | N | N |
| Priority Health | Y | Y | Y | Y | Y | Y |
| Ucare Grp | Y | Y | Y | Y | Y | Y |
| Totals | 7/8 | 8/8 | 8/8 | 5/8 | 7/8 | 5/8 |
Y, reporting criteria required; N, reporting criteria not required.
Denial Breakdown for SVHR-A
| Reason for Denial | No. Companies (%) |
|---|---|
| Always considered cosmetic | 25 (76%) |
| Experimental/investigational | 2 (6%) |
| Not mentioned | 6 (18%) |
Literature Review of Outcomes of CS
| Study | LOE | CS Technique | N | Defect Size (cm2) | Mesh Position | Mesh Material | Wound Characteristics | Mean Follow-up | Recurrence | SSI | Other Outcomes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Krpata et al 2012 | II | ACS | 55 | 531.0 ± 324.3 | Underlay | 83.9% biologic, 16.1% synthetic | 21.4% mesh infection at time of surgery | 9.1 mo | 14.30% | — | 19.6% major complications, 28.6% minor complications |
| Krpata et al 2012 | II | PCS | 56 | 471.5 ± 229.9 | Underlay | 25.5% biologic, 74.5% synthetic | 7.3% mesh infection at time of surgery | 6.8 mo | 3.60% | — | 10.9% major complications, 14.5% minor complications |
| Appleton et al 2017 | II | TAR (PCS) | 12 | — | Underlay | 75% biologic, 17% synthetic, 8% bioabsorbable | 92% VHWG 3 or 4 | 24 mo | 0% | 8.3% | 8.3% seroma, 8.3% small bowel obstruction |
| Fayezizadeh et al 2016 | II | TAR (PCS) | 77 | 306 ± 128 | RM | Biologic | 90% VHWG 3, 10% VHWG 2, 8% CDC 1, 34% CDC 2, 32% CDC 3, 26% CDC 4 | 28.2 mo | 12.50% | 28.% | 42.9% surgical site events |
| Posielski et al 2015 | II | TAR (PCS) | 32 | 760.1 ± 311.0 | RM | Synthetic | 84% CDC 1, 13% CDC 2, 3% CDC 3 | 9.0 mo | 6.30% | 12.% | 6.3% wound dehiscence, 3.1% seroma, 3.1% suture abscess |
| Petro et al 2015 | II | TAR (PCS) | 34 | 431 ± 207 | RM | 44.1% biologic, 55.9% synthetic | 38.2% clean, 61.8% contaminated | 18.0 mo | 14.70% | 23% | 35.3% SSO |
| Pauli et al 2015 | II | TAR (PCS) | 29 | 410 ± 283 | RM | 17% biologic, 24% synthetic | 62% CDC 1, 3% CDC 2, 28% CDC 3, 7% CDC 4 | 11 mo | 3% | 28% | 45% SSO |
| Girotto et al 2003 | II | ACS | 96 | — | Onlay | Synthetic | — | 26 mo | 22% | 27% | — |
| Jin et al 2007 | II | ACS | 22 | — | Onlay 77%, Underlay 18%, 5% sandwich | Biologic | — | 21.4 mo | 13.6%% | — | — |
| Espinosa-de-los-Monteros et al 2007 | II | ACS | 39 | 166 | Overlay | Biologic | — | 15 mo | 5% | — | 26% local complications |
| Diaz et al 2009 | II | ACS | 31 | 201 ± 155 | Inlay, onlay, interposition | — | — | 10.5 mo | 6.50% | 41.9% | 6.5% fistula formation |
ACS, anterior component separation; CDC, Center for Disease Control wound class; LOE, level of evidence; PCS, posterior component separation; RM, retromuscular; SSI, surgical site infection; SSO, surgical site occurrence; TAR, transversus abdominis release.
Literature Review of Outcomes of SVHR-P
| Study | LOE | N | Defect Size (cm2) | Mesh Position | Mesh Type | CS (%) | Mean Follow-up | Recurrence | SSI |
|---|---|---|---|---|---|---|---|---|---|
| McNichols et al 2018 | II | 106 | 225 | 49 onlay, 10 inlay, 10 underlay, 7 sandwich | 71% biologic, 29% synthetic | 68% | 373 d (6−2884) | 21.70% | 36.80% |
| Hutchison et al 2019 | II | 24 | 233.6 | 12.5% intraperitoneal, 8% onlay, 16% retromuscular, 12.5% no mesh | 17% biologic, 33% synthetic, 37.5% biosynthetic | 45.83% | 25.5 mo | 17% | 29% |
| Diaconu et al 2019 | III | 122 | 142 | 63% onlay, 11% inlay, 17% underlay, 8% sandwich | 69% biologic, 12% synthetic, 20% no mesh | 65% | 197 d | 23% | 13% |
| Shubinets et al 2017 | II | 1013 | N/A | N/A | N/A | N/A | 2 y | 7.90% | 5.60% |
| Warren et al 2015 | II | 43 | 130.7 | 74.% retromuscular, 11.6% PP, 4.6% onlay, 6.9% intraperitoneal, 2.3% none | 100% synthetic | 44% | 11.4 mo | 11.60% | 16.30% |
ACS, anterior component separation; CDC, Center for Disease Control wound class; CS, component separation; LOE, level of evidence; PCS, posterior component separation; RM, retromuscular; SSI, surgical site infection; SSO, surgical site occurrence; TAR, transversus abdominis release.
Fig. 1.The patient presented with a ventral hernia that protruded into his panniculus, neccesitating SVHR-P. A, Preoperative photograph demonstrating extent of ventral hernia and panniculus. B, Patient had AWR, with successful reduction of the hernia sac and restoration of abdominal contour.
Fig. 2.The patient presented with complex hernia and extensive abdominal scarring secondary to prior hernia repairs. A, Preoperative photograph demonstrating suboptimal skin scarring and abdominal contour. B, Intraoperative photograph showing the extent of the hernia defect and the low quality of the existing fascia. Patient required AWR with component separation (to aid in primary fascial closure) and soft tissue contouring (to aid with postoperative wound healing). C, The patient’s abdominal wall was successfully reconstructed with the necessary adjuncts of component separation and soft tissue contouring.
Characteristics of Complex Hernia Adapted from Slater et al
| Size and Location | Contamination and Soft Tissue | History and Risk Factors | Clinical Situation |
|---|---|---|---|
| ≥10-cm width | ASA Wound Class III or IV | Recurrent, prior mesh, prior component separation | Emergency |
| Parastomal, lumbar, lateral, and subcostal locations of hernia | Full-thickness abdominal wall defects | Risk factors for wound healing (ie, obesity, T2DM, age) | Intra-peritoneal mesh removal |
| Loss of domain ≥20% | Distorted anatomy | Increase intra-abdominal pressure | Multiple defects |
| Denervation | Other: skin grafts, wound ulcers/non-healing, open abdomen, disease-related, enterocutaneous fistula | Prior wound dehiscence | Component separations |
ASA, American Society of Anesthesiologsts; TWDM, type 2 diabetes mellitus.
Fig. 3.Indications for soft-tissue contouring and component separation procedures in abdominal wall reconstruction.